RhumbLine Advisers
PASG icon

RhumbLine Advisers’s Passage Bio PASG Stock Holding History

RhumbLine Advisers’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-39
Closed -$621 – 4295
2024
Q2 		$621 Hold
39
– – ﹤0.01% 4276
2024
Q1 		$1.06K Hold
39
– – ﹤0.01% 4142
2023
Q4 		$790 Hold
39
– – ﹤0.01% 4170
2023
Q3 		$515 Hold
39
– – ﹤0.01% 4231
2023
Q2 		$736 Buy
+39
New +$772 ﹤0.01% 4300
2022
Q2 		– Sell
-2,328
Closed -$144K – 3198
2022
Q1 		$144K Sell
2,328
-51
-2% -$4.2K ﹤0.01% 2827
2021
Q4 		$302K Buy
2,379
+24
+1% +$3.92K ﹤0.01% 2700
2021
Q3 		$469K Buy
2,355
+86
+4% +$20.5K ﹤0.01% 2576
2021
Q2 		$601K Buy
2,269
+808
+55% +$250K ﹤0.01% 2484
2021
Q1 		$511K Buy
1,461
+90
+7% +$38.4K ﹤0.01% 2483
2020
Q4 		$701K Buy
1,371
+567
+71% +$227K ﹤0.01% 2295
2020
Q3 		$211K Sell
804
-126
-14% -$43.4K ﹤0.01% 2667
2020
Q2 		$508K Buy
+930
New +$418K ﹤0.01% 2336

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RhumbLine Advisers's PASG Position: Q3 2024 in Review

RhumbLine Advisers sold out of Passage Bio (PASG) in Q3 2024, closing a stake of 39 shares — an estimated $621 sold.

RhumbLine Advisers first reported a position in PASG in Q2 2020 and held it in 13 quarters. The position peaked at $701K in Q4 2020. 44 funds tracked by Wall St. Rank hold PASG as of Q3 2024.

  • RhumbLine Advisers reported no remaining Passage Bio position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 39 Passage Bio shares in Q3 2024, an estimated $621.
  • RhumbLine Advisers first reported a position in Passage Bio in Q2 2020 and held it in 13 quarters.
  • RhumbLine Advisers's Passage Bio position peaked at $701K in Q4 2020.
  • 44 funds tracked by Wall St. Rank held Passage Bio as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.